Senseonics Holdings, Inc. 8-K

What Happened Senseonics Holdings, Inc. (together with Senseonics, Incorporated, the “Purchaser Parties”) announced the closing of local asset purchase agreements to acquire Ascensia Diabetes Care Holdings AG’s Eversense continuous glucose monitoring (CGM) commercial assets in four European countries. The Purchaser Parties and the Seller originally entered the local agreements on March 12, 2026 under a master asset purchase agreement dated December 31, 2025. Closings for Germany, Spain and Sweden occurred on June 1, 2026; the closing for Italy occurred on June 8, 2026. For finance and accounting purposes, the transfers are effective June 1, 2026. The transactions include the assumption of certain liabilities and obligations associated with the acquired European assets.

Key Details

• Parties: Purchaser Parties = Senseonics Holdings, Inc. and Senseonics, Incorporated; Seller = Ascensia Diabetes Care Holdings AG.
• Scope: Assets relate to commercial Eversense CGM activities in Germany, Spain, Sweden and Italy.
• Timeline: Local agreements entered March 12, 2026; master APA dated December 31, 2025; closings June 1, 2026 (Germany, Spain, Sweden) and June 8, 2026 (Italy).
• Accounting: Effective date for finance and accounting purposes is June 1, 2026; Purchaser Parties assumed certain related liabilities and obligations.

Why It Matters This filing confirms Senseonics has completed the planned acquisition of Eversense CGM commercial assets in key European markets, expanding its product footprint and taking on related responsibilities. For investors, the deal will be reflected in Senseonics’ financials as of June 1, 2026 and could influence revenue recognition, operating results and reported liabilities going forward. The 8‑K updates the market that the transactional milestones required for closing have been met.